6-K 1 a240718_6kxmorxvotingright.htm 6-K Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of July 2024
 
COMMISSION FILE NUMBER 001-38455
 
MorphoSys AG
 
Semmelweisstrasse 7
82152 Planegg
Germany
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨







On July 18, 2024, MorphoSys AG (the “Company”) published a notification on receipt of a letter of intent from Novartis BidCo Germany AG (pursuant to Section 43 (1) WpHG).



Exhibits











SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    MORPHOSYS AG (Registrant)

Date: July 18, 2024         
    By:    /s/ i.A. Kristina Grötsch
        Name: Kristina Grötsch
        Title:    Manager Investor Relations
    

    By:    /s/ i.A. Isabelle Degbegni    
        Name: Isabelle Degbegni
        Title:    Director Investor Relations